Hypertension

A panelist discusses how resistant hypertension is defined as persistently high blood pressure (>135/85 mm Hg) despite patients being on multiple antihypertensive medications and occurs in approximately 1 in 5 compliant patients.

New research suggests intensive blood pressure management may significantly benefit adults aged 80 and older, challenging previous treatment assumptions.

The FDA approves treprostinil inhalation powder, enhancing treatment options for patients with pulmonary arterial hypertension and interstitial lung disease.

FDA approves 12.5 mg chlorthalidone tablets, enhancing hypertension treatment options and aligning with clinical guidelines for better patient outcomes.

Patients provided with a Post-Acute Care Hypertension consultation and a method of daily medication reminders presented lower blood pressure on follow-up.

Data suggest that etripamil may be more effective than vagal maneuvers and oral prophylaxis, minimizing emergency department visits.

Orchestra BioMed’s Breakthrough Device designation could apply to nearly 8 million patients with uncontrolled hypertension and increased cardiovascular risk

Anemia can moderate the association between both conditions, increasing the risk of atherosclerotic cardiovascular disease.

Bhatt discusses his expectations for the future of cardiology in 2025, including GLP-1-RAs and the push towards combination therapy.

Ruff discusses his expectations for cardiology for the rest of 2025, including new research into GLP-1 receptor agonists.

Le discusses his anticipation for the results of upcoming cardiology trials in 2025, including HORIZON and Target-D.

Our Q1 2025 recap for cardiology spotlights 6 regulatory updates, 5 key trial announcements, and top expert perspectives in cardiac care.

A recap of 10 clinical trials in cardiovascular care to know from the American College of Cardiology 2025 Scientific Sessions.

Patients with PAH saw a 76% reduction in the composite of morbidity and mortality outcomes with sotatercept treatment.

Vallerie Mclaughlin, MD, discusses the ZENITH trial and its historic effects of sotatercept on mortality, transplant risk, and more in PAH.

Initiation of the MOMENTUM clinical trial will explore the prevalence of endogenous hypercortisolism in patients with resistant hypertension.

Our top 5 headlines featured an oral drug delivering 16% weight loss, notable blood pressure reductions from a hypertension treatment, and 3 key FDA decisions.

Topline data from the pivotal Launch-HTN and Advance-HTN trials met primary endpoints, supporting lorundrostat for uncontrolled or resistant hypertension.

New research tested how specialized hypertennsion medical curriculum impacted residents’ treatment of hypertensive urgency in the outpatient setting.

Merck announced robust efficacy data on the benefit of sotatercept for PAH in the STELLAR and ZENITH studies led to a loss of clinical equipoise in HYPERION.

Panelists discuss how chronic kidney disease (CKD) and uncontrolled hypertension create a damaging cycle, in which hypertension accelerates kidney damage while declining kidney function makes blood pressure harder to control.

Panelists discuss how evaluating uncontrolled hypertension in patients with early kidney dysfunction requires a careful investigation of underlying causes, including medication adherence, lifestyle factors, and potential secondary hypertension.

Panelists discuss how proper blood pressure measurement techniques require careful attention to patient positioning, cuff size selection, and standardized procedures to ensure accurate readings.

This listicle highlights 5 major approvals and 5 trial updates in cardiovascular care from 2024.